OliPass Strikes Ahead to Second Stage of Part 2a Trial for Ache Killer OLP-1002

SEOUL, South Korea, July 18, 2022 /PRNewswire/ — OliPass Company, a South Korea based mostly biotech specialised within the improvement of RNA therapeutics, introduced to maneuver ahead to the second stage of the Part 2a trial in Australia in osteoarthritis (OA) sufferers for ache killer OLP-1002, an SCN9A antisense PNA selectively inhibiting the expression of Nav1.7 sodium ion channel.

The Part 2a research consists of two phases. The primary stage is an open label research to establish an optimum dose vary assembly the goal efficacy and therapeutic length, during which sufferers obtain a single subcutaneous injection of 1, 3, 10, 25, 50 or 80 mcg (microgram) OLP-1002. Low doses and excessive doses have been simulated to inhibit Nav1.7 expression principally in peripheral nerves and the spinal wire, respectively. The second stage shall be a placebo-controlled double blind research to judge two doses of OLP-1002 chosen based mostly on the efficacy findings from the primary stage.

The corporate briefed on the medical readouts from the continued open label research as follows: Ache reductions every day had been marked and continued no less than a month in all of the 5 sufferers acquired 1 mcg OLP-1002. The common each day ache reductions by VAS had been strong and ranged from 60% to 85% over the interval of 30 days publish dose. The utmost was noticed round every week publish dose. Apparently the onset time was shorter than a number of hours. Ache reductions by WOMAC had been corresponding to these by VAS. Though the dosing and pharmacodynamic analysis of 80 mcg OLP-1002 have but to be accomplished, 50 mcg OLP-1002 seems to be the dose choosing up ache discount by CNS goal engagement.

“Given that the majority of ache sorts are peripheral by nature, the efficacy profiles noticed with 1 mcg OLP-1002 are very encouraging. The efficacy seems a lot stronger and persists far longer than identified with standard ache killers similar to NSAIDs, COX-2 inhibitors, opioid analgesics, and so forth. Moreover, the noticed onset time of a number of hours could be very engaging for managing acute ache together with post-operative ache. OLP-1002 shall hopefully substitute opioid ache killers. Thus, we’re very a lot thrilled to advocate 1 mcg OLP-1002 and a pair of mcg OLP-1002 for the second stage of the Part 2a research in OA sufferers,” famous Dr. Shin Chung, CEO of OliPass Company.

“The worldwide market of ache killers is estimated to be as massive as 100 billion USD per 12 months. Contemplating the market is at present prevailed with low cost generic ache killers with reasonable efficacy or compromised security, nonetheless, the market potential is actually far bigger. Lack of protected and efficient ache killers triggered the outbreak of opioid disaster. There are enormous unmet medical wants for ache killers with robust efficacy and good security. If a ache killer covers 10% of sufferers with refractory ache in developed international locations at an annual drug price of 1,000 to 2,000 USD, the ache killer is estimated to generate an annual gross sales of 30 to 60 billion USD,” mentioned Dr. Chung. “Endowed with robust efficacy, good security and lengthy therapeutic length, OLP-1002 is envisaged to turn out to be a primary line remedy for refractory continual ache and neuropathic ache. The forthcoming placebo-controlled double blind research shall outline the market potential of OLP-1002,” added Dr. Chung.

About OLP-1002

Individuals with a loss-of-function mutation of the SCN9A gene (i.e., SCN9A channelopathy) had been discovered insensitive to ache however with different sensory capabilities undisturbed. Because the SCN9A gene encodes Nav1.7 sodium ion channel subtype, selective inhibitors of Nav1.7 have been implicated to successfully and safely deal with ache. Sadly, there are ca 10 sodium ion channels structurally indistinguishable with small molecule inhibitors. Though small molecule inhibitors of Nav1.7 have been avidly evaluated, none have manifested robust analgesic efficacy and good security.

OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and subsequently anticipated to copy a lot of the phenotype of individuals with SCN9A channelopathy. In most of rodent ache mannequin research, OLP-1002 confirmed therapeutic exercise by goal engagement within the CNS. Within the meantime, medical readouts up to now recommend that peripheral goal engagement by OLP-1002 needs to be greater than adequate for ache administration in human sufferers. Thus, animal pharmacodynamic information needs to be translated with discretion.

About OliPass Company

OliPass Company is a public biotech firm listed in KOSDAQ in South Korea (ticker: KQ244460). The corporate is growing RNA therapeutics based mostly on its proprietary oligonucleotide platform known as OPNA (OliPass Peptide Nucleic Acid). OPNA was derived from PNA by rational chemical modifications with a purpose to enhance the cell permeability and RNA affinity. For therapeutic intervention, OPNA potently binds to focus on pre-mRNA, induces exon skipping, and yields mRNA splice variant. In contrast to different forms of RNA therapeutics, OPNA doesn’t require formulational help for in vivo therapeutic exercise.

SOURCE OliPass Company


Leave a Reply

Your email address will not be published. Required fields are marked *